NEW YORK – Aditxt announced on Monday that its subsidiary Pearsanta acquired MDNA Life Sciences' Mitomic blood-based early disease and cancer detection platform for upwards of $25 million.
The acquisition includes the Mitomic Endometriosis Test and the Mitomic Prostate Cancer Test, both currently under development, as well as a pipeline that includes tests for ovarian, pancreatic, liver, breast, stomach, esophageal, and colorectal cancers.
The transaction consisted of an upfront working capital payment of $500,000; a working capital payment at closing of $500,000; 50,000 shares of Aditxt common stock; warrants to purchase 50,000 shares of Aditxt common stock; 5,000 shares of Pearsanta preferred stock with a value of $25 million; and payments of up to $3.2 million, Aditxt said in a filing with the US Securities and Exchange Commission.
The Mitomic tests analyze mitochondrial DNA from blood samples to identify disease-associated biomarkers that lead to cancer-causing mutations. According to a presentation on MDNA's website, the assays use either PCR or digital PCR to detect these biomarkers.
"Integrating these assets into our portfolio represents a significant milestone for Pearsanta," Pearsanta CEO Ernie Lee said in a statement. "We believe that mitochondrial DNA is an exceptional liquid biopsy technology, and our entry into this transaction underscores our dedication to pioneering innovations that can significantly impact global patient care."
In December, Aditxt said it had signed an agreement to acquire Evofem Biosciences, a women's health company that markets a US Food and Drug Administration-approved contraceptive gel.